Supplemental Figures CAN 14-2043 Sahu et al.. Fig Supplementary S1 Figure S1. Chemotherapy agents generate PAF-R agonist formation in human SK23MEL melanoma.

Slides:

Advertisements

Similar presentations

Clancy-Thompson et al., Supplemental Figure 1 A B C Supplemental Figure 1: Mice were given intravenous B16 injection on day 0. A) After bearing tumors.

Advertisements

Supplementary Figure S1.

Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR

Synergistic antitumor effect of anti-CD40/CpG and 14

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Treatment with p38γ/p38δ inhibitor shows antifungal effects in vivo

Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth Alice Hervieu, Cédric Rébé,

Upregulation of Inflammatory Cytokines and Oncogenic Signal Pathways Preceding Tumor Formation in a Murine Model of T-Cell Lymphoma in Skin Xuesong Wu,

Jennifer R. Hamilton, Gayathri Vijayakumar, Peter Palese Cell Reports

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

Volume 21, Issue 4, Pages (October 2004)

Volume 138, Issue 2, Pages (February 2010)

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancer Robert E Merritt, MD, Ali Mahtabifard,

Volume 16, Issue 3, Pages (September 2009)

Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents Peter de Vries, Jack.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

IFN-γ induces TNF family ligand protein expression in vitro and in vivo. IFN-γ induces TNF family ligand protein expression in vitro and in vivo. (A and.

Molecular Therapy - Methods & Clinical Development

Topical Photodynamic Therapy Induces Systemic Immunosuppression via Generation of Platelet-Activating Factor Receptor Ligands Matheus Ferracini, Ravi.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

P300 depletion is lethal in cancer cells harboring loss-of-function mutations in CBP. A, synthetic-lethal effects assessed by colony formation assay. p300.

Augmentation of UVB Radiation-Mediated Early Gene Expression by the Epidermal Platelet-Activating Factor Receptor Jeffrey B. Travers, Howard J. Edenberg,

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Imatinib Mesylate in Cutaneous Melanoma

Treatment with NVP-AEW541 shows no efficacy in an s. c

A Enhanced Platelet-activating factor synthesis facilitates acute and delayed effects of intoxicated thermal burn injury Eric Romer1, Ravi P. Sahu1, Townsend.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Supplementary Figure 5: Effect of S48168 on normalized organ and skeletal muscle weights after 12 weeks of treatment for all the experimental groups from.

Effect of MI-773 dosing on long-term efficacy.

Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.

Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. Immune-mediated.

Jeffrey B. Travers Journal of Investigative Dermatology

Volume 26, Issue 4, Pages (April 2018)

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Stereotactic radiotherapy increases Tregs in tumors.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

Establishment of 12 PDX from BRAF inhibitor–progressed patients.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Tregs preferentially regulate TH2 cytokines in skin.

B. fragilis utilizes TLR2 signaling for its protective role against the development of colitis-associated cancer in mice. B. fragilis utilizes TLR2 signaling.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

GCS-100 selectively kills KRAS-addicted lung tumors.

NSD2-mediated methylation of PTEN at K349 dictates cellular sensitivity to DNA-damaging agents. NSD2-mediated methylation of PTEN at K349 dictates cellular.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Presentation transcript:

Supplemental Figures CAN Sahu et al.

Fig Supplementary S1 Figure S1. Chemotherapy agents generate PAF-R agonist formation in human SK23MEL melanoma cells Lipid extracts were obtained from 5 x 10 6 SK23MEL cells treated with 100  g/ml of chemotherapeutic agents, or 0.5% DMSO vehicle for various times, and tested for total PAF-R agonistic activity using PAF-R-positive KBP cells loaded with the calcium-specific dye Fura-2. The data are the Mean ± SE percentage of peak intracellular calcium response as a percentage of that induced by 1  M CPAF from at least three separate experiments. * Denotes statistically significant (P <0.05) changes in levels of PAF-R agonist activity from control values.

Figure S2. Left flank tumor growth: effect of chemotherapy and antioxidants on the growth of treated tumors. WT & PAFR-KO (Ptafr- /-) mice were placed on regular (NL) or antioxidant diet as in Fig. 3 for 10 days before implantation of dual B16F10 tumors, followed by intratumoral treatment with A) 36 mg/kg etoposide (n=9-12), or B) 15 mg/kg melphalan (n=9-11), or vehicle (n=7-10) every 3 days starting at day 6. The data depicted are the mean tumor volumes ± SE at Day 17 post-tumor implantation of tumors treated with chemotherapy, or vehicle, implanted on the left flank. Between WT & PAFR-KO mice, there were no statistically significant differences in the growth of chemotherapy- or vehicle-injected tumors. Moreover, there were no differences in the growth of the left flank tumors in response to vehicle treatment of the contralateral tumors. Fig Supplementary S2

A B Fig Supplementary S3

Figure S3. Effect of antioxidants on the etoposide-mediated increased tumor growth. WT & PAFR-KO (Ptafr-/-) mice were placed on antioxidant diet as in Fig. 3 for 10 days before placement of dual B16F10 tumors, followed by intratumoral treatment with A) 36 mg/kg etoposide (n=9-12) or B) 15 mg/kg melphalan (n=9-11) or vehicle (n=7-10) every 3 days starting at day 6. The data depicted are the mean ± SE of tumor volume of untreated tumors at Day 16 post-tumor implantation, in which the contralateral tumor was treated with etoposide. Antioxidants treatment did not affect the growth of undisturbed tumor in PAFR-KO mice. Statistical changes were noted between undisturbed tumor growth in WT and PAFR-KO mice treated with etoposide (P < 0.1) or melphalan (P < 0.01) on regular diet.

Fig Supplementary S4 Figure S4. CPAF and COX-2 inhibitor have no effect on B16F10 tumor growth in PAF-R- deficient mice. PAFR-KO (Ptafr-/-) mice implanted with a single tumor were treated at day 0 and every 3 days with ip injections of CPAF (250 ng) or vehicle or COX-2 inhibitor SC-236 (200 ng). Tumor growth was assessed over time as in Fig 4. The data depicted are the mean ± SE of tumor volume over time in 4-5 mice per experimental group.

Fig Supplementary S5 Figure S5. COX-2 inhibitor blocks etoposide-mediated augmentation of tumor growth. WT mice implanted with two tumors were treated with SC-236 (200 ng) or vehicle at day 0 and every 3 days, and underwent intratumoral treatment with PBS vehicle (n=11-13) or 36mg/kg etoposide (n=12-14) every 3 days starting at day 6. Tumor growth was assessed over time as in Fig 4. The data depicted are the mean ± SE of tumor volume of untreated tumors over time in which the contralateral tumor was treated with etoposide. Statistically significant differences were noted in tumor volumes (* P<0.05 and # P<0.1).

Fig Supplementary S6 Figure S6. Effect of COX-2 inhibitor on tumoral Treg levels. A group of FoxP3 EGFP WT mice (n=6-9) were implanted with a single B16F10 tumor followed by treatment either with COX-2 inhibitor (SC-236, 200ng) or vehicle (PBS, 100µl) i.p. starting at day 0 and repeated every 3 days until day 15. CPAF/vehicle treatments were given at day 0, 6 and 12. Mice were sacrificed at days 6, 9, 12, 15 and 18 and tumors harvested and processed for the analysis of EGFP positive cells as a surrogate marker for Tregs by flow cytometry and qPCR studies. A) Data (flow cytometry) are the Mean ± SE of EGFP+ cells (normalized to vehicle control mice) in CPAF and SC CPAF groups in tumors over the period of time. B) A representative flow analysis for tumoral EGFP+ cells at day 9 in CPAF and SC CPAF groups are shown. C) qPCR analysis for the EGFP mRNA normalized to CD3e in the CPAF and SC CPAF groups are shown. * Denotes statistically significant difference (P<0.05) between CPAF versus SC CPAF groups.